Diabetes Mellitus and Related Disorders



Diabetes Mellitus and Related Disorders





OVERVIEW AND ASSESSMENT


In 2010, diabetes mellitus was estimated to affect almost 26 million Americans. This is more than 8% of the U.S. population. Unfortunately, this number is expected to double, if not triple, by 2050.

It is thought that the factors contributing to the explosion of diabetes are an aging population, increased prevalence of type 2 diabetes mellitus in youth, growing numbers of ethnic minorities, and the increasing trend of obesity (>65% of American adults are overweight or obese).

The cost of caring for people with diabetes is staggering. In 2007, the United States spent $174 billion on diabetes care alone. This is two to three times more than the health care costs of those without diabetes. By 2030, it is estimated that the United States will spend more than $333 billion on diabetes mellitus.

Diabetes mellitus is the leading cause of blindness, kidney failure, and lower limb amputations. People with diabetes are two to four times more likely to be diagnosed with heart disease, three times more likely to have dental disease, and twice as more likely to suffer from depression.

This is a very serious disease with even more serious consequences. All nurses must stay current on the latest care recommendations. Screening for this disease is essential because early treatment leads to a reduction of morbidity and mortality.


Insulin Secretion and Function



  • Insulin is a hormone secreted by the beta cells of the islet of Langerhans in the pancreas.


  • Small amounts of insulin are released into the bloodstream in response to changes in blood glucose levels throughout the day (basal secretion).


  • Increased secretion or a bolus of insulin, released during meals, helps maintain euglycemia.


  • Through an internal feedback mechanism that involves the pancreas and the liver, circulating blood glucose levels are maintained at a normal range of 60 to 100 mg/dL.


  • Insulin is essential for the utilization of glucose for cellular metabolism as well as for the proper metabolism of protein and fat.



    • Carbohydrate metabolism—insulin affects the conversion of glucose into glycogen for storage in the liver and skeletal muscles, and allows for the immediate release and utilization of glucose by the cells.


    • Protein metabolism—amino acid conversion occurs in the presence of insulin to replace muscle tissue or to provide needed glucose (gluconeogenesis).



    • Fat metabolism—storage of fat in adipose tissue and conversion of fatty acids from excess glucose occurs only in the presence of insulin.


  • Glucose can be used in the endothelial and nerve cells without the aid of insulin.


  • Without insulin, plasma glucose concentration rises and glycosuria results.



    • Absolute deficits in insulin result from decreased production of endogenous insulin by the beta cell of the pancreas.


    • Relative deficits in insulin are caused by inadequate utilization of insulin by the cell.


Classification of Diabetes


American Diabetes Association (ADA). (2013). Standards of medical care in diabetes (position statement). Diabetes Care, 36(Suppl. 1), S11-S66.


Type 1 Diabetes Mellitus

Type 1 diabetes mellitus (T1DM) was formerly known as insulindependent diabetes mellitus and juvenile diabetes mellitus.



  • Little or no endogenous insulin, requiring injections of insulin to control diabetes, prevent ketoacidosis and sustain life.


  • Only 5% to 10% of all people with diabetes have T1DM.


  • Etiology is not well understood: includes autoimmune, viral, and certain histocompatibility antigens as well as genetic components.


  • Clinical manifestation is abrupt with classic symptoms of polydipsia, polyphagia, polyuria, and weight loss.


  • Most commonly seen in patients under age 30 but can be seen in older adults.


Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) was formerly known as non-insulin-dependent diabetes mellitus or adult-onset diabetes mellitus.



  • Caused by a combination of insulin resistance and relative insulin deficiency—some individuals have predominantly insulin resistance, whereas others have predominantly deficient insulin secretion, with little insulin resistance.


  • Approximately 90% to 95% of people with diabetes have T2DM.


  • Etiology: strong hereditary component, commonly associated with obesity.


  • Usual presentation is slow and typically insidious with symptoms of fatigue, weight loss, poor wound healing, and recurrent infection.


  • Found primarily in adults over age 30; however, it is now more frequently seen in younger adults and adolescents who are overweight.


  • People with this type of diabetes may be treated with insulin, but are still referred to as having T2DM.


Gestational Diabetes Mellitus

Gestational diabetes mellitus (GDM) is defined as the onset of carbohydrate intolerance that initially presents during pregnancy and resolves upon delivery.



  • Affects approximately 2% to 10% of pregnancies; however, the new diagnostic criteria may yield that as many as 18% of pregnancies are affected by GDM.


  • Women with GDM have a 35% to 60% chance of developing T2DM diabetes in the next 10 to 20 years. They should be screened for diabetes 6 to 12 weeks postpartum and continue to have lifelong screening at least every 3 years.


  • GDM is associated with significant risk of maternal and fetal complications.


  • Due to the worldwide increases of both obesity and diabetes rates, the American Diabetes Association (ADA) made the recommendation that all pregnant women should be screened for the presence of T2DM at the initial prenatal visit using the standard diagnostic criteria (2011). Women who are negative for T2DM at that time should then be screened for GDM at 24 to 28 weeks of gestation.


  • Screening for GDM is done using a 75-g 2-hour oral glucose tolerance test (2-h OGTT).


  • The American College of Obstetricians and Gynecologists (ACOG) issued a Committee statement asserting that they have not yet adopted the new diagnostic criteria for gestational diabetes (as listed on page 944) and will continue to use the diagnostic criteria established by either Carpenter and Coustan or the National Diabetes Data Group. Both of these screening methods utilize a 100-g 3-h OGTT, require two abnormal results and the threshold for these results is higher than the newer criteria.


Diabetes Due to Other Causes



  • Genetic defects of insulin secretion and/or insulin action.


  • Pancreatic diseases (such as cystic fibrosis, pancreatitis, and pheochromocytoma).


  • Drug-induced (such as corticosteroids and medications used to treat HIV/AIDS).


Prediabetes



  • Prediabetes is an abnormality in glucose values intermediate between normal and overt diabetes.


  • Associated with obesity, dyslipidemia, and hypertension; prediabetes is a potent risk factor for developing T2DM and cardiovascular disease.


  • Every effort should be made to assist the patient with aggressive lifestyle modifications (diet, exercise, and weight loss) to prevent the progression from prediabetes to overt T2DM.


  • There are two forms of prediabetes, based on when glucose is elevated. Patients that simultaneously have both forms of prediabetes have a very high risk of developing T2DM.



    • Impaired fasting glucose (IFG)—defined as having fasting blood glucose levels of 100 to 125 mg/dL.


    • Impaired glucose tolerance (IGT)—defined as blood glucose measurement of 140 to 199 mg/dL using a 2-hour OGTT.



Laboratory Tests


American Diabetes Association (ADA). (2013). Standards of medical care in diabetes (position statement). Diabetes Care, 36(Suppl. 1), S11-S66.

Global International Diabetes Federation (IDF)/International Society of Pediatric and Adolescent Diabetes (ISPAD). (2011). Guideline for diabetes in childhood and adolescence. Available: www.ispad.org/NewsFiles/IDF-ISPAD_Diabetes_in_ Childhood_and%20Adolescene_Guidelines_2011.pdf.

Laboratory tests include those tests used to make the diagnosis as well as measures to monitor short- and long-term glucose control. See Box 25-1 for details of when and how often to screen adults, adolescents, and children for T2DM.



Blood Glucose


Description



  • Fasting blood sugar (FBS), drawn after at least an 8-hour fast, to evaluate circulating amounts of glucose.


  • Postprandial test, drawn usually 2 hours after a well-balanced meal, to evaluate glucose metabolism.


  • Random glucose, drawn at any time, without regard to the time of last caloric intake.


Nursing and Patient Care Considerations



  • For fasting glucose, make sure that patient has maintained 8-hour fast overnight; sips of water are allowed.


  • Postprandial test, drawn usually 2 hours after a well-balanced sampling because this affects the test results.


  • For postprandial glucose, advise patient that no additional food or caloric beverages should be consumed during the 2-hour interval.


  • For random blood glucose, note the time and content of the last meal.


Diagnostic Criteria and Treatment Goals for Blood Glucose Values



  • American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) diagnostic blood glucose values for diabetes mellitus in children, adolescents, and nonpregnant adults are:



    • FBS greater than or equal to 126 mg/dL, confirmed with a repeat test on another day.


    • Random blood sugar (regardless of time of last caloric intake) 200 mg/dL or higher and presence of classic symptoms of diabetes (polyuria, polydipsia, polyphagia, and weight loss). This test does not need to be repeated nor does the diagnosis need to be confirmed with another test.


    • Fasting blood glucose result of 100 to 125 mg/dL is prediabetes (IFG) and demands close follow-up and repeat monitoring at least every 3 years.


  • Blood glucose treatment goals for many nonpregnant adults with diabetes mellitus:



    • Premeal: 70 to 130 mg/dl (ADA) or <110 mg/dL (AACE).


    • 1 to 2 hours postmeal: less than 180 mg/dL (ADA) or <140 mg/dL (AACE).


  • The International Diabetes Federation (IDF)/International Society of Pediatric and Adolescent Diabetes (ISPAD) blood glucose treatment goals for children and adolescents:



    • Premeal: 90 to 145 mg/dL.


    • Postmeal: 90 to 180 mg/dL.


    • Bedtime: 120 to 180 mg/dL.


  • ADA and AACE blood glucose treatment goals for women with gestational diabetes:



    • Premeal: 95 mg/dL or lower.


    • 1 hour postmeal: 140 mg/dL or lower.


    • 2 hours postmeal: 120 mg/dL or lower.


  • ADA and AACE blood glucose treatment goals for pregnant women with preexisting diabetes:



    • Premeal, bedtime: 60 to 99 mg/dL.


    • 1 hour postmeal: 100 to 129 mg/dL.




Oral Glucose Tolerance Test


Description

The oral glucose tolerance test (OGTT) evaluates insulin response to glucose loading. FBS is obtained before the ingestion of a glucose load and blood samples are drawn at timed intervals.


Nursing and Patient Care Considerations



  • Advise patient that for accuracy in results, certain instructions must be followed:



    • Usual diet and exercise pattern must be followed for 3 days before OGTT.


    • During OGTT, patient must refrain from smoking and remain seated.


    • Hormonal contraceptives, salicylates, diuretics, phenytoin, and nicotinic acid can impair results and may be withheld before testing based on the advice of the health care provider.


Diagnostic Criteria Using the 75-g 2-h OGTT



  • ADA and AACE diagnostic OGTT values when screening for diabetes mellitus in children, adolescents, and nonpregnant adults:



    • 200 mg/dL or higher at the 2-hour interval.


    • 140 to 199 mg/dL at the 2-hour interval is prediabetes (IGT) and demands close follow-up and repeat monitoring at least every 3 years.


  • ADA and AACE diagnostic blood glucose values for gestational diabetes performed 24 to 28 weeks gestation: (only need to meet the limits of one of the following values):



    • Fasting of 92 mg/dL or higher, or


    • 180 mg/dL or higher at the 1-hour interval, or


    • 153 mg/dL or higher at the 2-hour interval.


Glycated Hemoglobin (Glycohemoglobin, HbA1c, A1c)


Description

Measures glycemic control over a 60- to 120-day period by measuring the irreversible reaction of glucose to hemoglobin through freely permeable erythrocytes during their 120-day life cycle. Currently used to screen for diabetes as well as to monitor control.


Nursing and Patient Care Considerations



  • No prior preparation, such as fasting or withholding insulin/medications, is necessary.


  • Test results can be affected by red blood cell disorders (eg, thalassemia, sickle cell anemia), room temperature, ionic charges, and ambient blood glucose values.


  • Many methods exist for performing the test, making it necessary to consult the laboratory for normal values.


  • Should be performed at least twice yearly in patients whose diabetes is stable and well controlled. Quarterly (every 3 months) testing is recommended for patients who have had treatment changes/adjustments or whose diabetes is not well controlled.


Diagnostic Criteria and Treatment Goals for A1c Values



  • ADA and AACE diagnostic A1c values when screening for diabetes mellitus in children, adolescents, and nonpregnant adults:



    • 6.5% or higher (should be confirmed with repeat A1c or fasting glucose or OGTT).


    • 5.7% to 6.4% (ADA) or 5.5% to 6.4% (AACE) is considered prediabetes and demands close follow-up and repeat monitoring at least every 3 years.


  • The joint position statement (2009) of the ADA, the American College of Cardiology Foundation, and the American Heart Association asserts that in general, the A1c goal for nonpregnant adults is less than 7%, but that this must be individualized based on life expectancy, duration of diabetes, history of hypoglycemia, presence of microvascular complications, and presence of cardiovascular disease.


  • The IDF/ISPAD treatment A1c goal for children is between 7.5% and less than 9% based on age and ability to detect hypoglycemia.


  • The ADA and AACE treatment A1c goal of pregnant women with preexisting type 1 or type 2 diabetes is less than 6% (if without excessive hypoglycemia).


  • Because GDM is diagnosed late in pregnancy, the A1c is not a reliable marker of control (3-month average) and the fructosamine value (2- to 3-week average) may be more meaningful.


Fructosamine Assay


Description

Glycated protein with a much shorter half-life than glycated hemoglobin, reflecting control over a shorter period, approximately 14 to 21 days. May be advantageous in patients with hemoglobin variants that interfere with the accuracy of glycated hemoglobin tests.


Nursing and Patient Care Considerations



  • Note if patient has hypoalbuminemia or elevated globulins because test may not be reliable.


  • Should not be used as a diagnostic test for diabetes mellitus.


  • No special preparation or fasting is necessary.


C-Peptide Assay (Connecting Peptide Assay)


Description

Cleaved from the proinsulin molecule during its conversion to insulin, C-peptide acts as a marker for endogenous insulin production.


Nursing and Patient Care Considerations



  • Test can be performed after an overnight fast or after stimulation with Sustacal, intravenous (IV) glucose, or 1 mg of Glucagon SubQ.


  • Absence of C-peptide indicates no beta cell function, reflecting possible T1DM or insulinopenia in T2DM.


Autoantibody Testing


Description

An autoantibody is an antibody (a type of protein) manufactured by the immune system that is directed against one or more of the
individual’s own proteins. Islet cell autoantibodies are strongly associated with the development of T1DM. The appearance of autoantibodies to one or several of the autoantigens—GAD65, IA-2, or insulin—signals an autoimmune pathogenesis of β-cell destruction. The positivity of any or all of these autoantibodies in the presence of hyperglycemia is used to confirm the diagnosis of T1DM. Because T1DM affects such a small number of the population, generalized screening would be costly and therefore is not recommended.


Nursing and Patient Care Considerations



  • No special preparation or fasting is necessary.


  • Screen patients with T1DM for other autoimmune disorders such as hypothyroidism and celiac disease.


GENERAL PROCEDURES AND TREATMENT MODALITIES


Blood Glucose Monitoring


Accurate determination of capillary blood glucose assists patients in the control and daily management of diabetes mellitus. Blood glucose monitoring helps evaluate effectiveness of medication; reflects glucose excursion after meals; assesses glucose response to exercise regimen; and assists in the evaluation of episodes of hypoglycemia and hyperglycemia to determine appropriate treatment.



Insulin Therapy


Insulin therapy involves the subcutaneous injection of rapid-, short-, intermediate-, or long-acting insulin at various times to achieve the desired effect (see Table 25-1). Short-acting regular insulin as well as some of the rapid-acting analogs can also be administered intravenously. Currently, there are approximately 10 types of insulin available in the United States; most of these are human insulin manufactured synthetically (analogs). Beef and pork insulins are no longer available in the United States.











Table 25-1 Insulin Products Available in the United States and Their Onset, Peak, Duration, Route, Pregnancy Category







































































































































TYPE


ONSET


PEAK


DURATION


ROUTE


PREGNANCY CATEGORY


Rapid-Acting Analogs


Insulin aspart (Novolog)


<15 minutes


1-3 hours


3-5 hours


SQ, pump, IV


B


Insulin glulisine (Apidra)


<15 minutes


1 hour


2-4 hours


SQ, pump, IV


C


Insulin lispro (Humalog)


<15 minutes


1 hour


3 1/2-41/2 hours


SQ, pump


B


Short-Acting Human Insulin


Insulin injection Humulin R


30 minutes


2-4 hours


6-8 hours


SQ, IV


B


Novolin R


30 minutes


21/2-5 hours


8 hours


SQ, IV


B


Intermediate-Acting Basal


Insulin isophane susp. (NPH)


1-2 hours


6-12 hours


18-24 hours


SQ


B


Humulin N


1.5 hours


4-12 hours


24 hours


SQ


B


Novolin N







Long-Acting Basal Analogs


Insulin detemir (Levemir)


1 hour


None


12-24 hours


SQ


B


Insulin glargine (Lantus)


1 hour


None


≥24 hours


SQ


C


Premixed Insulin


Analog Preparations


Novolog Mix 70/30


<15 minutes


2-4 hours


24 hours


SQ


B


Humalog Mix 75/25


<15 minutes


01/2 -1.5 hours


24 hours


SQ


B


Humalog Mix 50/50


<15 minutes


1 hour


16 hours


SQ


B


NPH and Regular Suspensions


Humulin 70/30


30 minutes


2-12 hours


24 hours


SQ


B


Novolin 70/30


30 minutes


2-12 hours


24 hours


SQ


B


Notes: No FDA-approved insulins derived from beef are available in the United States. They were discontinued in 1998 because of concerns about bovine spongiform encephalopathy (BSE; “mad cow disease.”)


Iletin II Regular (Pork), Iletin II NPH (Pork), Humulin Lente, and Humulin Ultralente were all discontinued by the manufacturer (Lilly) in 2005 because of reduced demand and high cost.


Exubera (inhaled insulin) was discontinued by Pfizer in late 2007 because of poor sales.





Self-Injection of Insulin



  • Teaching of self-injection of insulin should begin as soon as the need for insulin has been established.


  • Teach the patient and another family member or significant other.


  • Use written and verbal instructions and demonstration techniques.


  • Teach injection first because this is the patient’s primary concern; then teach loading the syringe.


  • See Procedure Guidelines 25-2 for instructions on technique.


  • For patients who have difficulty with the injection procedure, insulin pens are available that use a prefilled cartridge that delivers the set dose of insulin. A few devices also deliver the insulin by jet stream without a needle.


Community and Home Care Considerations



  • Assist the patient in deciding whether to reuse insulin syringe at home. The patient may decide to do so due to cost; however, reuse has become controversial because the newer, finer needles may become dull or bent after one or two injections, causing tearing of tissue, which can lead to lipodystrophy.



    • Needles should not be reused if painful injection or irritated site results.


    • Needle should be recapped by patient and stored in a clean place if it is going to be reused.


  • Assist the patient in obtaining the appropriate syringe size and needle length for injections.



    • Determine if there are visual or dexterity issues that make a syringe with gradations farther apart more desirable.


    • There is no medical reason to use needles >8 mm in length, even in obese patients. Needle lengths of 4, 5, and 6 mm are reliable to deliver medication into the subcutaneous space. To prevent inadvertent intramuscular injection in patients who are thin, the needle can be inserted at a 45-degree angle (rather than at a 90-degree angle) and/or the skin should be folded prior to needle insertion.



  • Advise the patient that it is not necessary to use alcohol to wipe off the top of the vial or prepare the skin before injection. It has not proved to result in lower rate of infection and adds cost and time to the procedure. The patient should maintain good hygiene.


  • Instruct the patient to store insulin currently in use in a clean, secure place away from direct sunlight and heat. In-use insulin does not require refrigeration. Check manufacturer recommendations for when to discard insulin vials and pens; recommendations may vary from 10 to 28 days after opening. All unopened vials/pens must be stored in the refrigerator until initial use.


  • Check manufacturer’s recommendations before teaching the patient how to mix insulin; for example, the patient should know that insulin glargine and insulin detemir must never be mixed with any other insulin. Other manufacturers’ websites containing recommendations are Aventis (www .aventis.com), Eli Lilly (www.lilly.com), and Novo Nordisk (www. novonordisk.com).


  • Avoid prefilling syringes if at all possible because manufacturers have no data on the stability of insulin stored in syringes for long periods. If prefilling is the only option, store in refrigerator or suggest an insulin pen injection device.


  • Help the patient develop a plan for the disposal of needles. There are no federal regulations for discarding needles used at home; however, needles and lancets can pose a risk for injury. The rules and regulations regarding sharps disposal are different in towns and counties around the country, so advise the patient to check with local sanitation or health departments.




    • Sharps can be placed in a hard plastic or metal container with a tightly secured lid after use.


    • More information on disposal can be obtained from the Environmental Protection Agency www.epa.gov/osw/nonhaz/industrial/medical/med-home.pdf) or by contacting the Coalition for Safe Community Needle Disposal (800-643-1643 or www.safeneedledisposal.org).








Figure 25-1. Insulin regimens.


Insulin Regimens



NPH or Long-Acting Analog Only



  • NPH is not used as frequently as basal insulin because of the availability of the newer analog basal insulins that are more reliable and associated with less hypoglycemia.


  • Used as monotherapy only in T2DM as a supplement for better glucose control when patients are still capable of producing some exogenous insulin.


  • Traditionally, administered at bedtime to assist with controlling early-morning hyperglycemia.


  • Can be given as a morning dosage to assist with normalization of glucose during the afternoon and evening.


  • NPH can also be given twice daily (morning and bedtime) to eliminate afternoon hypoglycemia yet provide nighttime coverage. Typically, 2/3 to 3/4 of the daily dosage is given before breakfast and 1/3 to 1/4 is given at bedtime.


NPH/Regular or NPH/Rapid-acting Insulin



  • Short-acting regular insulin or rapid-acting lispro, glulisine, or aspart insulin is added to NPH to promote postprandial glucose control.


  • Short- or rapid-acting insulin added to morning NPH controls glucose elevations after breakfast.


  • Increased blood glucose levels after supper can be controlled by the addition of short- or rapid-acting insulin before supper.


  • NPH and regular, lispro, glulisine, or aspart insulin given before breakfast and before supper is termed a “split-mix” regimen, providing 24-hour insulin coverage. However, there is an increased risk of nocturnal hypoglycemia (2:00 to 3:00 a.m.) when NPH is given before supper.


Intensive Insulin Therapy

Jul 20, 2016 | Posted by in NURSING | Comments Off on Diabetes Mellitus and Related Disorders

Full access? Get Clinical Tree

Get Clinical Tree app for offline access